Eli Lilly and Co
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
Atomoxetine Phase 2 Study in Japanese Adult Patients With Attention Deficit/Hyperactivity Disorder (ADHD)
- First Posted Date
- 2007-09-17
- Last Posted Date
- 2011-07-27
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 45
- Registration Number
- NCT00530335
- Locations
- 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan
Study of Enzastaurin Versus Placebo With Pemetrexed for Participants With Advanced or Metastatic Lung Cancer
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2007-09-17
- Last Posted Date
- 2020-07-01
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 160
- Registration Number
- NCT00530621
- Locations
- 🇵🇹
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Porto, Portugal
Concurrent Pemetrexed, Cisplatin and Radiation Therapy in Patients With Stage IIIA/B Non Small Cell Lung Cancer
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Drug: Pemetrexed Phase 1Drug: Pemetrexed Phase 2Drug: Cisplatin Phase 1Procedure: Radiation TherapyDrug: Cisplatin Phase 2
- First Posted Date
- 2007-09-14
- Last Posted Date
- 2013-07-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 49
- Registration Number
- NCT00529100
- Locations
- 🇨🇦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toronto, Ontario, Canada
Open-Label Study of Duloxetine in the Treatment of Children and Adolescents With Major Depressive Disorder
- First Posted Date
- 2007-09-14
- Last Posted Date
- 2011-10-24
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 72
- Registration Number
- NCT00529789
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bellevue, Washington, United States
Chemotherapy for Patients With Osteosarcoma
- First Posted Date
- 2007-08-31
- Last Posted Date
- 2011-06-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 32
- Registration Number
- NCT00523419
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Newcastle-Upon-Tyne, Tyneside, United Kingdom
A Study of Pemetrexed in Children With Recurrent Cancer
- Conditions
- OsteosarcomaMedulloblastomaSarcoma, Ewing'sNeuroblastoma (Measurable Disease)Neuroblastoma (MetaiodobenzylguanidinePositive Evaluable)RhabdomyosarcomaEpendymomaNon-brainstem High-grade Glioma
- Interventions
- First Posted Date
- 2007-08-27
- Last Posted Date
- 2011-02-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 72
- Registration Number
- NCT00520936
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Arcadia, California, United States
A Study for Patients With Schizophrenia
- First Posted Date
- 2007-08-27
- Last Posted Date
- 2009-10-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 654
- Registration Number
- NCT00520923
- Locations
- 🇿🇦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Randburg, South Africa
Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2007-08-24
- Last Posted Date
- 2011-08-10
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 260
- Registration Number
- NCT00520676
- Locations
- 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tao-Yuan, Taiwan
Study With IMC-A12 (Cixutumumab) in Patients Who Have Not Previously Been Treated With Chemotherapy With Metastatic Prostate Cancer
- Conditions
- Adenocarcinoma of the Prostate
- Interventions
- Drug: IMC-A12 (Cixutumumab)
- First Posted Date
- 2007-08-24
- Last Posted Date
- 2018-07-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 41
- Registration Number
- NCT00520481
- Locations
- 🇺🇸
ImClone Investigational Site, Seattle, Washington, United States
A Study of Ramucirumab in Participants With Metastatic Renal Cell Carcinoma
- Conditions
- Metastatic Renal Cell Carcinoma
- Interventions
- Biological: Ramucirumab
- First Posted Date
- 2007-08-14
- Last Posted Date
- 2014-06-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 39
- Registration Number
- NCT00515697
- Locations
- 🇺🇸
ImClone Investigational Site, Seattle, Washington, United States